Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TwHF vs Sulfasalazine in Active Rheumatoid Arthritis
NCT00062465Phase 2Completed
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Tripterygium wilfordii in rheumatoid arthritis (RA) (2 arms), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Primary endpoint: American College of Rheumatology 20% Improvement at 24 weeks. Started Jun 2003; status: completed.
02
Drugs
Tripterygium wilfordii
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00062465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062465.